CCL4 and Hepatic fibrosis: MSC engraftment has shown ideal efficacy in a bleomycin‐induced pulmonary fibrosis mouse model.[49] In 2004, Isao Sakaida revealed the transplantation of MSCs alleviated carbon tetrachloride (CCL4)‐induced hepatic fibrosis in mice.[50] In 2005, Florian demonstrated that MSCs are a potential therapy targeting renal failure.[51] Although the mechanisms of fibrosis have not been clarified yet, cellular therapy is still an alternative therapeutic strategy for fibrosis.